Rejuveron Life Sciences AG

Rejuvenate Biomed announces positive results from Phase 1b clinical trial with RJx-01 in sarcopenia. Amazing news coming from one of our major investments, Rejuvenate Biomed. Sarcopenia - age-related progressive loss of muscle mass and strength - is one of the most debilitating conditions affecting people when they age. The process of muscle decay starts usually at around 30 years, so if you are reading this, you're probably already affected by it... Solving this disease is key to help people enjoying their lives as they age, and help government and private insurance companies manage the costs related to a large portion of the population being placed in a position of dependence due to their feebleness in old age.  The extraordinary success of obesity drugs which is undoubtedly THE great success story of the life sciences and pharma sector over the last 18months (move along, mRNA vaccines) should not distract from the fact that one common side effects is the loss of muscle addition of strength. This makes the search for a Sarcopenia drug all the more worthwhile, since pharmas are likely to go shopping for companies enabling them to soften muscle addition of strength loss side effects. To be continued.... #RejuvenateBiomed #Sarcopenia #ClinicalTrials #AgingPopulation #MuscleLoss https://lnkd.in/emVP6UGf

We're raising the bar on healthy aging! Today, we are excited to announce a $75M Series B round co-led by Catalio Capital Management and Apeiron Investment Group, with Mubadala Capital joining the syndicate. This funding will help us accelerate our mission to develop therapies that promote healthy aging and prolong healthspan and lifespan for everyone. We are also expanding into the Middle East, with Rejuveron Life Sciences' new office in Abu Dhabi. This will allow us to build strategic partnerships with local research centers and clinics, such as NYU Abu Dhabi. We look forward to hitting the ground running, accelerating the path from benchside to bedside. Join us in welcoming Boost Neuroscience to the Rejuveron family. Tackling neurodegenerative disease, and developing pro-cognitive therapies, Boost is a cutting-edge company developed and spun out by Stanford's Nobel Prize winning neuroscientist, Dr. Thomas Südhof. We're grateful to all our supporters who continue to help us make our mission possible! With thanks especially to: Christian Angermayer, Aaron Weaver, CFA,  Alaa Halawa, R. Jacob Vogelstein, Aksana Labokha, Caleb Morgret, Pierre-Antoine Mudry, Gabor Gyulveszi, Karim Allam and Talha-Khan Aquil. Stay tuned for more exciting developments! https://lnkd.in/ePXXFnfq